Apricus Biosciences Inc (APRI) Stock Price, Quote, News and Overview
NASDAQ:APRI - Nasdaq -
APRI Quote, Performance and Key Statistics
0.22
-0.01 (-4.35%)
The current stock price of APRI is 0.22 null. In the past month the price increased by 15.79%. In the past year, price decreased by -90.52%.
About APRI
Company Profile
Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT' drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.
Company Info
Apricus Biosciences Inc
11975 EL CAMINO REAL SUITE 300
SAN DIEGO CA 92130
CEO: Richard W. Pascoe
Phone: 858-222-8041
Apricus Biosciences Inc / APRI FAQ
What is the stock price of Apricus Biosciences Inc today?
The current stock price of APRI is 0.22 null. The price decreased by -4.35% in the last trading session.
What is the ticker symbol for Apricus Biosciences Inc stock?
The exchange symbol of Apricus Biosciences Inc is APRI and it is listed on the Nasdaq exchange.
On which exchange is APRI stock listed?
APRI stock is listed on the Nasdaq exchange.
What is Apricus Biosciences Inc worth?
Apricus Biosciences Inc (APRI) has a market capitalization of 6.20M null. This makes APRI a Nano Cap stock.
What are the support and resistance levels for Apricus Biosciences Inc (APRI) stock?
Apricus Biosciences Inc (APRI) has a resistance level at 0.23. Check the full technical report for a detailed analysis of APRI support and resistance levels.
Should I buy Apricus Biosciences Inc (APRI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APRI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APRI, evaluating the profitability, health, valuation and growth aspects
- Apricus Biosciences Inc (APRI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Apricus Biosciences Inc (APRI) Sales and EPS estimates to see what analysts future expectations are.
- Apricus Biosciences Inc (APRI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Apricus Biosciences Inc (APRI) Insider and Institutional Ownership to learn about the owners and their transactions.
- Apricus Biosciences Inc (APRI) Stock Chart to make your own analysis
- Apricus Biosciences Inc (APRI) Latest news and press-releases to stay up to date.
Does Apricus Biosciences Inc (APRI) stock pay dividends?
APRI does not pay a dividend.
What is the Price/Earnings (PE) ratio of Apricus Biosciences Inc (APRI)?
Apricus Biosciences Inc (APRI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).
APRI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to APRI. When comparing the yearly performance of all stocks, APRI is a bad performer in the overall market: 98.39% of all stocks are doing better.
APRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to APRI. APRI may be in some trouble as it scores bad on both profitability and health.
APRI Financial Highlights
Over the last trailing twelve months APRI reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 13.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -176.71% | ||
| ROE | -239.05% | ||
| Debt/Equity | 0 |